HBV and HCV therapy

Pietro Lampertico, Alessio Aghemo, Mauro Viganò, Massimo Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.

Original languageEnglish
Pages (from-to)484-509
Number of pages26
JournalViruses
Volume1
Issue number3
DOIs
Publication statusPublished - Oct 22 2009

Keywords

  • HBV DNA
  • HCV RNA
  • Nucleos(t)ide analogues
  • Peg-IFN
  • Resistance
  • Ribavirin
  • SVR

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'HBV and HCV therapy'. Together they form a unique fingerprint.

Cite this